Top Stocks For 2012-2-11-12

Crown Equity Holdings, Inc. (CRWE)

Crown Equity Holdings Inc’s selection of Core Link reflects recent diversification beyond CRWE’s original charter as a provider of services and knowledge to small business owners taking their own companies public. In addition to these services, Crown Equity Holdings Inc has transitioned into a multifaceted media organization that publishes clients’ news online; sells advertising adjacent with its digital network targeted at a high-income audience; designs, hosts and maintains websites; produces marketing videos from concept to final product; crafts press releases and articles for maximum SEO; develops email campaigns; and forges branding campaigns to bolster client company images.

Crown Equity Holdings, Inc. together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

VoIP can turn a standard Internet connection into a way to place free phone calls. The practical upshot of this is that by using some of the free VoIP software that is available to make Internet phone calls, you’re bypassing the phone company (and its charges) entirely. VoIP is a revolutionary technology that has the potential to completely rework the world’s phone systems.

Crown Equity Holdings Inc. (CRWE) is pleased to announce that it has entered into a joint venture to deploy VoIP (Voice over Internet Protocol) technology delivering voice, video and data services to residential and commercial customers. The joint venture company is Crown Tele Services Inc. which was a wholly-owned subsidiary of Crown Equity Holdings Inc.

Commenting on the joint venture, Kenneth Bosket, President of Crown Equity Holdings Inc., said: “We are excited to deliver VoIP communications solutions specifically designed to meet the business and residential market needs with Mr. Kumar who has extensive experience in this fast-growing global market.”

For more information please visit official website of CRWE: http://www.crownequityholdings.com

Antares Pharma Inc. (AMEX:AIS) reported financial and operating results for the second quarter ended June 30, 2011. Quarter and Recent Highlights: Increased both product revenue and total revenue quarter over quarter and year over year. Announced positive results from a VIBEX� MTX clinical pharmacokinetic trial in patients with rheumatoid arthritis (RA) and remain on track for a New Drug Application (NDA) filing in 2012. An additional patent application has been filed based on the data obtained from the study results.Announced an exclusive licensing agreement with Watson Pharmaceuticals, Inc. for the commercialization of Anturol� gel, for treatment of patients with overactive bladder (OAB), currently under review by the Food and Drug Administration (FDA).Ended the quarter with $33.3 million in cash.

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products.

Voyager Oil & Gas, Inc. (AMEX:VOG) announced record oil and gas production, revenue and adjusted EBITDA for the second quarter ended June 30, 2011. During the quarter ended June 30, 2011, Voyager reported revenues of $1,666,535. This represents an increase of 101% from $832,621 in the first quarter ending March 31, 2011 and an increase of 925% from $162,548 in the quarter ended June 30, 2010. This increase in revenue is due primarily to production from 24 gross (1.13 net) producing Bakken and Three Forks wells as of June 30, 2011.

Voyager Oil & Gas, Inc. engages in the exploration and production of oil and gas in the United States.

Inovio Pharmaceuticals, Inc. (AMEX:INO) reported financial results for the quarter ended June 30, 2011. Total revenue was $2.4 million and $5.5 million for the three and six months ended June 30, 2011, compared to $1.1 million and $2.5 million for the same periods in 2010. Total operating expenses for the three and six months ended June 30, 2011, were $7.6 million and $15.0 million as compared to $6.1 million and $11.9 million for the same periods in 2010.

Inovio Pharmaceuticals, Inc., through its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases.